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RESUMEN
El aceite de oliva en nutrición clínica.
Los avances en el conocimiento del metabolismo lipídico están
permitiendo establecer las bases científicas de los efectos saluda-
bles del aceite de oliva. En los países del área Mediterránea, la mor-
talidad cardiovascular es menor que en otros, aunque la
concentración de colesterol en sangre es similar. Es muy probable
que la capacidad cardio-protectora del aceite de oliva se relacione
con otros factores de riesgo, algunos de los cuales son poco o com-
pletamente desconocidos. Las propiedades bioquímicas, biológicas
y nutricionales del aceite de oliva son peculiares y permiten su apli-
cación en la nutrición clínica. Los beneficios del aceite de oliva se
correlacionan con su acción sobre el metabolismo lipídico y el siste-
ma cardiovascular. Un aumento moderado en la ingesta de grasa
monoinsaturada (aceite de oliva), a expensas de los carbohidratos,
es la recomendación en pacientes con diabetes e hipertrigliceride-
mia. En nutrición clínica, el aceite de oliva también tiene efectos be-
neficiosos en enfermedades relacionadas con respuestas
inflamatorias y autoinmunes, como la artritis reumatoide. La compo-
sición química del aceite de oliva virgen extra contribuye a las nece-
sidades diarias de ácidos grasos esenciales y de antioxidantes,
especialmente en situaciones patológicas de deficiencia en vitami-
na E. Sin duda, el aceite de oliva (virgen extra) tiene máxima rele-
vancia, por su contenido de ácido oleico (18:1n-9) y compuestos
minoritarios, en la nutrición clínica..
PALABRAS-CLAVE: Aceite de oliva; Ácidos grasos monoin-
saturados; Nutrición enteral; Nutrición parenteral; Dieta Mediterrá-
nea.
SUMMARY
Olive oil in clinical nutrition.
The different beneficial effects of olive oil have a rational and
scientific basis due to advances in the knowledge of lipid
metabolism. The evidence that for a similar plasma cholesterol
concentration, the rate of cardiovascular deaths is lower in the
Mediterranean countries than in other ones, suggests that the
beneficial effects of olive oil may not be only related to the known
quantitative changes in plasma lipoproteins, but also to other, as
yet unknown or little known, anti-atherogenic factors. The
peculiarities of olive oil in terms of certain biochemical, biological
and nutritional characteristics, open up a field of application in
normal clinical practice. The benefits of olive oil in clinical nutrition
corre late  wi th  i ts  act ion  on l ip id  metabo l i sm and the
cardiovascular system. Even a moderate increase in the ingestion
of monounsaturated fats and a reduction in the ingestion of
carbohydrates could be more advantageous in those patients with
diabetes and hypertriglyceridemia and/or in those where loss of
weight is not a priority. Different studies have also demonstrated
the benefits of olive oil in different inflammatory and autoimmune
diseases, such as rheumatoid arthritis. The chemical composition
of extra virgin olive oil contributes to daily requirements of
essential fatty acids and active antioxidant nutrients in vitamin E
deficiency. This particular and well-balanced situation [oleic acid
(18:1n-9) and minor components in an ideal ratio] undoubtedly
has a significant relevance in human clinical nutrition..
KEY-WORDS: Olive oil; Monounsaturated fatty acids;
Enteral nutrition; Parenteral nutrition; Mediterranean diet.
1. INTRODUCTION
Olive oil is not usual oil, as we can well see in this
special edition of the journal Grasas y Aceites. The
different beneficial effects of olive oil, known from
time immemorial, today have a rational and scientific
basis due to advances in the knowledge of lipid
metabolism, as well as in other fields of biology,
confirming epidemiological and nutritional data
known for so many centuries.
The peculiarities of olive oil in terms of certain
biochemical, biological and nutritional characteristics,
open up a field of application in normal clinical practice.
This includes the lipid component in enteral as well as
in parenteral nutritional formulations. Anyway, it
should keep in mind the importance of olive oil in oral
nutrition under certain pathological conditions, such
as those patients with disorders of carbohydrate and
lipid metabolism, and other special conditions.
Strong evidence exists, derived from
epidemiological, clinical and intervention studies,
that the lipids in the diet, quantitatively and
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qualitatively, are jointly responsible, along with the
‘‘new lifestyles’’, for a series of diseases or
pathological conditions coined as ‘‘diseases of
civilisation’’.
The establishment of a causal relationship
between lipids in the diet and the concentration of
cholesterol in the blood, high blood pressure and
vascular disease, and other pathological conditions,
drove the need to modify eating habits by reducing
calories from saturated fats and increasing the ratio
of monounsaturated to total fats.
2. OLIVE OIL AND ORAL NUTRITION
The tendency, in earlier times, to increase the
ingestion of polyunsaturated fatty acids (PUFA), has
been definitively shown to be less favourable, not
only in the sense of inducing quantitative changes in
the lipoprotein profile, but also in substantially
decreasing the antioxidant potential of the food. This
has led to the need to provide more antioxidant
vitamins (e.g. vitamin E) to avoid the induced- or
auto-oxidation of these PUFA and therefore
increasing the aggression by reactive oxygen
species (ROS) and lipid peroxidation.
Nutritionists, clinicians, epidemiologists and other
professionals have recently directed their attention
on the influence of olive oil in the diet for several
reasons:
· Olive oil has unique physicochemical and
sensorial characteristics.
· The historic consumption of olive oil in the
Mediterranean area where, despite the high
average ingestion of fats (approximately 40%
of the total calories), the plasma cholesterol
levels are relatively low.
· The evidence that for a similar plasma cholesterol
concentration, the rate of cardiovascular deaths is
lower in the Mediterranean countries than in
other ones, which suggests that the beneficial
effects of olive oil may not be only related to the
known quantitative changes in plasma
lipoproteins, but also to other, as yet unknown
or little known, anti-atherogenic factors.
· Olive oil appears to be protective against
certain tumours such as those found in breast,
colon and prostate (Braga and La Vecchia,
1989; Newmark, 1999; Owen t al., 2000a,b).
· The beneficial effects of a monounsaturated fat
when it is substituted for saturated fatty acids
(SFA) or carbohydrates in people with
hypercholesterolemia or type 2 diabetes
(Garg, 1998; ADA, 2002; Ros, 2003).
Moreover, the chemical composition of extra virgin
olive oil contributes to daily requirements of essential
fatty acids (n-6 and n-3 PUFA) and active antioxidant
nutrients (tocopherols) in vitamin E deficiency. The
phenolic and polyphenolic compounds pre ent in extra
virgin olive oil, with their high anti-oxidant power, act
as savers or protectors of tocopherols in different
metabolic pathways, increasing in this way, directly
or indirectly, the availability of high bioactive
quantities of tocopherol to the cellular membranes.
This particular and well-balanced situation [oleic acid
(18:1n-9) and minor components in an ideal ratio]
undoubtedly has a significant relevance in human
clinical nutrition.
From the point of view of oral nutrition, different
regional population studies, where distinct eating
habits prevail, have clearly demonstrated the
significant differences in the incidence and
prevalence of death and morbidity in the pathologies
related to cholesterol disturbances, such as
cardiovascular and neoplastic diseases. One
example of that is the classic ‘‘study of the seven
countries’’ (Keys, 1980; Keys et al., 1986). Compared
to the diet of the countries in northern Europe, the
Mediterranean Diet was associated to a low death
rate for all causes and for ischaemic heart disease in
the following fifteen years in the male cohort with
ages between 40-50 years at the beginning of the
study.
Traditionally, the benefits of olive oil in oral
nutrition correlate with its action on lipid metabolism
and the cardiovascular system. However, in the last
few years, other beneficial effects of olive oil are of
major interest in the field of gastroenterology. Olive
oil may reduce the risk of cholelithiasis through
multiple mechanisms, including its cholagogue effect
by cholecystokinin stimulation (Baggio et al., 1988;
Bravo and Flora, 1998). Additionally, a diet rich in
olive oil is associated with a high percentage of
gastric peptic ulcer healing and acts as a resistance
factor in gastric ulcerogenesis from non-steroidal
anti-inflammatories. On the other hand, different
studies have also demonstrated the benefits of olive
oil in different inflammatory and autoimmune
diseases, such as rheumatoid arthritis (Darlington
and Ramsey, 1991). Cognitive protection against
deterioration in the elderly is another clinical factor
related to the intake of olive oil.
However, where possibly better evidence exists in
oral nutrition, in relation to the benefits of
monounsaturated fats and to olive oil in particular (apart
from its benefits already mentioned regarding cholesterol
metabolism and cardiovascular risk), it is in regard to its
beneficial effects in patients with type 2 diabetes. In
fact, the diet is a cornerstone in the treatment of these
patients. The objective of dietetic management of
patients with type 2 diabetes is not only to improve
metabolic control of their hyperglycaemia but also,
concomitantly and obligatory, to reduce the high
cardiovascular risk (particularly for coronary disease)
by optimising plasma cholesterol levels until they reach
levels currently recommended for this population.
The development of type 2 diabetes is disposed
to the high consumption of calories, especially of
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fats, which used to be associated with development
of obesity and overweight (Ohlsson et al., 1985).
However, studies carried out in the last decade have
shown that the different fatty acids have different
effects on carbohydrate metabolism. As the high
consumption of PUFA induces a decrease in HDL
cholesterol, along with the known effects on the
oxidability of LDL (Hayne et al., 1989; Swiburn et al.,
1991), it must not exceed the recommended 7% of
the calories. By using different experimental models,
monounsaturated fatty acids (MUFA) consumed
instead of carbohydrates by patients with type 2
diabetes have the following effects (Garg et al., 1988;
Rasmussen et al., 1993; Campbell et al., 1994):
1.  Improve the glucose tolerance and perip-
heral sensitivity to insulin.
2.  Lower mean blood glucose and 24-hour
urine glucose levels.
3.  Lower the postprandial glucose, insulin and
triglycerides.
4.  Lower the requirements for exogenous in-
sulin.
5.  Lower the triglyceride levels and higher
HDL cholesterol.
6.  Decrease in numbers with high blood pres-
sure.
However, diets rich in monounsaturated fats do
not improve fasting glucose or HbA1C. When energy
ingestion and weight is maintained constant, diets
low in saturated fats and rich in carbohydrates or
enriched with MUFA reduce the plasma HDL
cholesterol values equivalently. The concern raised
by this is that MUFA rich diets may increase energy
consumption and weight in a voluntarily outside
controlled environment. As earlier demonstrated in a
meta-analysis (Garg, 1998), there is no evidence of
weight increase in subjects with type 2 diabetes as
long as energy intake is right.
Certainly, the latest recommendations of the
American Diabetes Association include increasing
carbohydrates or MUFA up to 60-70% of the total
energy requirements to replace SFA (evidence level
B) (ADA, 2002). Even a moderate increase in the
ingestion of monounsaturated fats and a reduction in
the ingestion of carbohydrates could be more
advantageous in those patients with diabetes and
hypertriglyceridemia and/or in those where loss of
weight is not a priority.
3. OLIVE OIL IN CLINICAL NUTRITION: AN
   ALTERNATIVE LIPID
The peculiarities of olive oil that we have seen up
to now, in terms of biochemical, biological and
nutritional characteristics, open up a field of
application in normal clinical practice as the lipid
component in enteral and parenteral nutrition
formulas.
Lipids are widely used in artificial nutrition,
fundamentally for their high calorific value, isotonicity
and their ability to ‘‘save’’ great quantities of
carbohydrates, which can be harmful to critically ill
patients. In fact, before the introduction of lipids into
artificial nutrition and in emulsions, glucose was the
only available source of non-protein calories that
entailed on many occasions certain complications
such as hepatic lipogenesis, a marked increase in
carbon dioxide production and an increase in insulin
requirements in diabetic patients.
The maximum tolerated carbohydrate load is 4
mg/kg/min in healthy subjects and 7 mg/kg/min in
post-operative patients (Phillips and Odgers, 1986).
Administering approximately 50% of non-protein
calories in lipid form avoids the harmful effects of an
excessive glucose load and results in a positive
nitrogen balance (Nordenstrom et al., 1983).
However, the introduction of lipids into artificial
and parenteral nutrition signified a logical advance
as a vehicle for energy and as a contributor of
essential fatty acids, which the body cannot
synthesize and has to obtain from the diet. The
essential fatty acids [linoleic (18:2n-6) and -linolenic
(18:3n-3) acids that belong to the n-6 and n-3
families, respectively] are the starting points for the
elongation and desaturation mechanisms. There is
the formation of more longer and unsaturated fatty
acids, acting as structural elements in cell
membranes and as precursors of highly bioactive
eicosanoids (prostaglandins, leukotrienes and
tromboxanes) by cyclo- and lipoxygenases
coordinated pathways.
The initial developments in lipid emulsion for the
formulation of parenteral diets used seed oils
(soybean and sunflower oils) as the only fats, which
predominantly contained triglycerides with
long-chain unsaturated fatty acids from series n-6
and n-3 (Skeie et al., 1983; Ekman et al., 1987;
Venus et al., 1989; Kinsella and Lokesh, 1990). It
was extremely high the concentration of PUFA and
the ratio of linoleic acid to -linolenic acid, both in
absolute and in relative terms, clearly exceeding the
current daily recommendations. The total daily
calories as linoleic acid should be 1-2%, with a
contribution of -linolenic acid to reach a ratio of
n-6/n-3 of around 4/1 to 10/1. As linoleic and
-linolenic acids are involved into similar metabolic
systems for the synthesis of their active metabolites,
having -linolenic acid a higher affinity for those
enzyme systems, any alteration in the concentration
of n-3 fatty acids will have an effect on the
metabolism of n-6 fatty acids.
Those formulations, based on only one class of
seed oil, will be predisposed to produce
non-balanced bioactive compounds at many cellular
sites. They potentially induce different undesired
pathologies, including thromboses, atheromatous
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plaques, allergies, inflammations and even cellular
proliferation phenomena. Highly unsaturated oils
offer a ‘‘fertilised field’’ sensitive to ROS. By this way,
free radicals continuously produced can damage all
types of cellular macromolecules (proteins, lipids,
carbohydrates and nucleic acids). If the exposure to
these oxidative sources is intense and the material
for its oxidation is highly reactive, the defence
antioxidant mechanisms of the body can be
insufficient for its neutralisation and lead to the
well-known oxidative stress. This pathology is
particularly serious in critically ill patients, the majority
who are on parenteral nutrition, with no optimal
antioxidant capability, and a high susceptibility to
immunodepression and inflammatory processes
(Halliwell and Gutteridge, 1985).
Therefore, in the last decade, it has made
considerable efforts to develop new studies in clinical
nutrition. The model mediates a decrease in the
contribution of unsaturated fatty acids and modifies
the pattern of lipids into the emulsions (BNF, 1993).
Both conceptual changes have to improve distinct
physiological responses. It appeared that olive oil
has clear advantages by modulating the oleic acid
content of emulsions and satisfying optimum ratios to
the different fatty acid families (MUFA: oleic acid/n-6
PUFA: linoleic acid/n-3 PUFA: a-linolenic acid). The
results of this new emulsion, in relation to the classic
emulsion with soybean oil, show a similar supply of
energy; beneficial effects on lipid metabolism (Aviram
and Eias, 1993; Mangas-Cruz et al., 2001); limited risk
of lipid peroxidation both in vitro and in vivo due to
the high content of MUFA and unsaponifiable rich in
natural antioxidants (Scaccini et al., 1992; Visioli et al.,
1994; Harris et al., 1997; Visioli and Galli, 1998; Visioli
et al., 1998); and a more balanced production of
long-chain PUFA. Olive oil is safety compare to other
fats (Bach and Babayan, 1982; Liebermann et al.,
1990; Ythier-Moury et al., 1990; Calder et al., 1991;
Garnier-Chevereau et al., 1991; Brouwer et al., 1993;
Granato et al., 2000) and supplies a fatty acid
composition similar to hose found in maternal milk
(Tomarelli, 1988; Nestle NS, 1992), which once again
reinforces the concept that olive oil is a dietary
element of enormous biological value in clinical
nutrition.
4. OLIVE OIL AND ENTERAL NUTRITION
Although a large amount of evidence exists on the
benefits of olive oil as an integral part of the
Mediterranean Diet, the data available on its effects
as a component in enteral formulations is still scarce.
Clinical trials carried out on different enteral
formulations enriched with MUFA have been focused
on specific clinical situations. Throughout this
section, we will analyse the available data in the
literature of two clinical situations of major interest,
the diabetic patient and the patient with active
inflammatory intestinal disease. 
4.1. Patients with diabetes mellitus
The dietary recommendations established for
diabetic patients have varied throughout the time,
due to greater knowledge of the disease, advances
in nutrition and the treatment possibilities.
Hyperglycaemia was early controlled at the expense
of severe restricting carbohydrate intake. Later, diets
very rich in carbohydrates were recommended,
especially complex ones and with a large amount of
fibre. Nowadays, the American Diabetes Association
(ADA, 2003) has relaxed the restrictions on the
amount of carbohydrates and MUFA, which
contributes to personalize macronutrient intake
depending on the type of diabetes, the nutritional
status and the lipid profile (Franz et al., 2002).
Compared to diets enriched in carbohydrates, those
rich in MUFA improve the glucose control and the
lipid profile of patients with type 2 diabetes mellitus
(Garg, 1998). Unfortunately, there is not the same
level of confidence on the benefits of enteral
f rmulations enriched in MUFA. It is reflected in ADA
recommendations, where a standard formulation
(50% carbohydrate) and formulations rich in fats and
poor in carbohydrates can be found. We consider
that enteral nutrition constitutes the first line
nutritional support in practically all clinical situations.
Therefore, it is of special interest to understand the
influence of different enteral formulations on the
metabolic control in diabetics (Sax and Souba,
1993). If high-MUFA enteral formula reproduces the
favourable effects on glucose metabolism as shown
for oral diets remains to be fully established and
represents an active research line in clinical nutrition.
In 1989, Peters and Davidson reported a lower
glycaemic response in 10 type 1 diabetic patients
after stimulated tube feeding with a low-carbohydrate
/high-MUFA/high-fibre enteral formula [16.7% of
proteins, 50% of fats (35.7% as MUFA) and 33.3% of
carbohydrates] compared to a high-carbohydrate/
low-fat/low-fibre standard formula [16.7% of proteins,
30.1% of fats (0.4% as MUFA) and 53.2% of
carbohydrates]. They concluded that the quantity of
total carbohydrates in the formulation was the main
determining factor in the glucose postprandial
metabolism and that MUFA could be involved (Peters
and Davidson, 1992). It was difficult to evaluate the
role of MUFA in this experience, since the quantity of
fats (MUFA) in the formulation varied as
carbohydrates did.
The effect of MUFA-enriched enteral formula on
glucose control in type 2 diabetic patients has been a
focus of different studies (Sturner et al., 1994;
Sanz-Paris et al., 1998; Thomas et al., 1998). In
some of them, a breakfast test has shown benefits by
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reducing glucose and insulin plasma levels when
MUFA replaced to complex carbohydrates. These
findings were partially confirmed with a longer
follow-up time (Craig et al., 1998). Recently, we have
collaborated in a Phase IV multicentre study for
comparing the effect of two commercial formulations
on the glucose metabolic control of 63 type 2 diabetic
patients with indications of enteral nutritional support
by nasogastric tube, due to neurological deficit or
head/neck cancer surgery (Leon et al., 2004). The
first formulation, rich in MUFA and poor in
carbohydrates, consisted of 16.7% of proteins, 50% of
fats (3.8 g/100 mL of MUFA) and 33.3 % of
carbohydrates; the second one was rich in complex
carbohydrates and poor in fats [15% of proteins, 31% of
fats (no MUFA) and 54% of carbohydrates]. The results
obtained after a mean time treatment of 13 days
showed that MUFA-enriched formulation had a neutral
effect on plasma glucose control and lipid profile, and
a better gastrointestinal tolerance, in comparison
with the carbohydrate-enriched formulation.
4.2. Patients with inflammatory intestinal
     disease
When enteral nutrition is well tolerated,
constitutes an efficient therapy in the treatment of
Crohn’s disease (CD). As shown previously,
increased levels of n-6 PUFA enhance the formation
of eicosanoids and cytokines with powerful
pro-inflammatory action (James t al., 2000),
suggesting that diets rich in n-6 PUFA are not
recommended under active CD. However, enteral
formulation rich in oleic acid (olive oil) combined with
steroids was found to be efficient against active CD
but with a high variability in the rate of remission
(Gonzalez-Huix et al., 1993; Middleton et al., 1995).
Surprisingly, a recent study on 62 patients with active
CD, the rate of remission in the group treated with
enteral formulation rich in oleic acid (synthetic origin)
was lower than that found with the formulation rich in
linoleic acid (Gassull et al., 2002). This effect was
independent of the total amount of long-chain
triglycerides (LCT) and differences could be partially
attributed to the nature of the matrix fat from which
oleic acid is supplied. In addition, we do not rule out
the involvement of minor compounds from extra
virgin olive oil on remission of active CD.
5. OLIVE OIL IN EMULSION FOR PARENTERAL
   NUTRITION
Parenteral nutrition contributes to the provision of
amino acids and energy supply from glucose and
lipids. Emulsions for parenteral nutrition may contain
water, glycerol, egg yolk phospholipids, and soybean
oil at concentrations of 20 to 30%, meaning the
presence of LCT (Garcia de Lorenzo et al., 2003).
When used, the proportion of medium-chain
triglycerides (MCT) does no exceed 50% of total
triglycerides (Garnacho-Montero t al., 2002a). More
ecently, structured triglycerides with long- and
medium-chain fatty acids in the glycerol backbone
are also available.
Emulsions based on olive oil (EBOO: 80% olive
oil and 20% soybean oil) have 20% SFA, 60% MUFA
and 20% PUFA, and provide of a-tocopherol (36 mg/L
vs. 9 mg/L from emulsions based on LCT). Animal
studies show that EBOO improves hepatic regeneration
after hemihepatectomy and induces not much lipid
peroxidation and oxidative damage (Ok et al., 2003). In
traumatised patients, subjected to parenteral nutrition
with EBOO there is an increase in the plasma levels of
vitamin E as compared with soybean oil-containing
emulsion (Bernard et al., 2000; Reimer et al., 2000). In
a randomised double-blind study on burns patients,
Garcia de Lorenzo et al. (2000) observed that the
EBOO-group maintained adequate plasma levels of
essential fatty acids compared to the group treated with
MCT/LCT. Similar results have been described for
children after EBOO for 2 months (Goulet t al.,
1999). Compared to soybean oil, they better
tolerated EBOO and exhibited a lower peroxidation
index.
In several clinical studies, the use of LCT for
parenteral nutrition has been associated with growth
of bacteria in catheter of surgical patients (Snydman
et al., 1982), bacteraemia in critical ill neonates
(Freeman et al., 1990), and pneumonias and
infections related to the catheter in traumatised
patients (Battistella et al., 1997). The role of PGE2 in
these processes is a matter of discussion. PGE2 has
different immunomodulatory effects depending on its
concentration: higher than 10-9 M is capable of
activating T suppressor cells and suppressing
blastogenesis of T and B cells, production of certain
cytokines and immunoglobulins, mitogen response
and phagocyte function; whereas lower than 10-9 M
promotes lymphocyte differentiation and formation of
a tibodies. EBOO may achieve a decrease in PGE2,
but it remains to be established if the effect continues
in critical situations, such as advanced sepsis,
severe burns or multiple traumas.
Another clinical aspect of EBOO is its ability to
maintain the integrity of the intestinal barrier, conferring
 new dimension to these emulsions that goes beyond
a simple qualitative nutritional substitution. Our group
has verified that EBOO induces less bacterial
translocation compared to classic emulsions with LCT
and LCT/MCT (Garnacho-Montero et al., 1999).
Additionally, we have shown by using an animal model
that this effect operates with a minor depression in
phagocyte capacity of the mononuclear system after
a bacteraemia with Gram-negative bacilli (Garnacho-
Montero et al., 2002b), and with an atrophy of the
intestinal epithelial cells, especially in the jejunum
(Ortiz-Leyba et al., 2001).
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